Background: Observational studies have assessed the association between total antioxidant capacity of the diet and risk of diabetes mellitus. However, results from these studies were not entirely consistent. In the current systematic review and dose-response meta-analysis, we aimed to determine the association between dietary total antioxidant capacity (TAC) and the risk of prediabetes and diabetes mellitus.
Methods: A systematic literature search of authentic electronic resources including PubMed/Medline, Embase, Scopus, ISI Web of Science and China National Knowledge Infrastructure (CNKI) was carried out to find the relevant articles published up to November 2024. Random-effects or fixed-effects models were used to aggregate the relative risks (RRs) and their 95% confidence intervals (CIs) where appropriate. Heterogeneity across the studies were determined using the Cochran's test and -square ( ) statistics.
Results: A total of 10 observational studies (five cohort, three case-control and two cross-sectional studies) were included in our meta-analysis. The pooled results indicated that higher dietary TAC was significantly associated with lower risk of prediabetes (RR = 0.58; 95% CI: 0.34-0.97; = 0.039) and diabetes mellitus (RR = 0.71; 95% CI: 0.58-0.87, = 0.001). In addition, dose-response analysis showed a linear trend association between dietary TAC and risk of diabetes mellitus (RR = 0.928; 95% CI: 0.842-1.023, = 0.131, = 0.078). Subgroup analyses showed the significant inverse association between dietary TAC and diabetes mellitus in mean age <50 and sample size <5,000 (RR = 0.26, 95% CI: 0.16-0.41, < 0.001), and there was no evidence of heterogeneity ( = 0.939; = 0.0%). Meanwhile, there was also an inverse association between dietary TAC and diabetes mellitus in Western countries (RR = 0.79; 95% CI: 0.68-0.92, = 0.003), with less evidence of heterogeneity ( = 0.226; = 36.7%).
Conclusion: Overall, higher dietary TAC was inversely associated with the risk of prediabetes and diabetes mellitus. Further well-designed prospective studies or randomized controlled trials are needed to validate the present findings.
Systematic Review Register: (PROSPERO), CRD42024611235.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893433 | PMC |
http://dx.doi.org/10.3389/fnut.2025.1541734 | DOI Listing |
PLoS One
March 2025
Public Health Research Center, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Introduction: Family history of cardiovascular disease (CVD) is an independent risk factor for coronary heart disease, and the risk increases with number of family members affected. It offers insights into shared genetic, environmental and lifestyle factors that influence heart disease risk. In this study, we aimed to estimate the association of family history of CVD and its risk factors, as well as the number of affected parents or siblings, with the prevalence of major cardiometabolic risk factors (CRFs) such as hypertension, dysglycemia, dyslipidemia and obesity in a sample of young adults.
View Article and Find Full Text PDFHealth Syst Reform
December 2025
Department of Obstetrics and Gynecology, University of Benin, Nigeria.
Diabetes mellitus, once a rare diagnosis in precolonial and early post-colonial Nigeria, now has the highest prevalence and fatality rates in sub-Saharan Africa. This increased prevalence is attributed to rising population affluence characterized by sedentary lifestyles and higher consumption of processed and ultra-processed foods. The burden is further exacerbated by a poorly responsive healthcare system.
View Article and Find Full Text PDFJ Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFJ Immunol
February 2025
Orthopedics Department, Central Hospital of Ezhou, Ezhou, China.
Diabetic nephropathy is a severe chronic complication characterized by cytotoxicity, inflammation, and fibrosis, ultimately leading to renal failure. This study systematically investigated the effects of the PARP1 inhibitor PJ-34 on high glucose-induced cytotoxicity, inflammation, and fibrosis in HK-2 cells, as well as its improvement on neuropathic pain response and transforming growth factor β (TGFβ) expression in a type 1 diabetes mellitus diabetic nephropathy mouse model. Through cellular and animal experiments, we observed that PJ-34 significantly enhanced the proliferative capacity of cells damaged by high glucose, reduced apoptosis, and decreased the release of proinflammatory factors TGFα, interleukin-6, and interleukin-1β.
View Article and Find Full Text PDFPLoS One
March 2025
Laboratory of Epidemiology and Geoprocessing of Amazon, University of the State of Pará (UEPA), Belém, Brazil.
Severe Acute Respiratory Syndrome is an important public health problem in Brazil due to the large number of cases. It has a high mortality rate related to risk factors that include systemic arterial hypertension, type 2 diabetes mellitus, male gender and advanced age. This cross-sectional and ecological study analyzed the spatial distribution of this disease related to the evolution of COVID-19 cases and their epidemiological, demographic, socioeconomic and public health policy conditions in the administrative districts of Belém, state of Pará, in the eastern Brazilian Amazon, from 2021 to 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!